Gosselies, Belgium (PRWEB) February 05, 2014
Euroscreen, a private drug development company, announced today that it will present its Phase I clinical development candidate, ESN364, at the 11th International Symposium on GnRH on Monday, February 10th in Salzburg, Austria. Dr. Graeme Fraser, Director of Drug Discovery, will present on the discovery and development of ESN364 and describe the pharmacology of its unique mechanism of action to modulate the GnRH axis.
ESN364 is a proprietary, oral, small molecule NK3 antagonist discovered and optimized at Euroscreen. This is the first NK3 antagonist optimized for the purpose of the treatment of Women’s Health Disorders. "Our drug candidate series represents a safe and powerful new approach to the treatment of diseases such as endometriosis, uterine fibroids and PCOS. Moreover, the NK3-mediated mechanism of action of ESN364 provides a more refined modulation of the HPG axis permitting chronic therapy, unlike the existing GnRH approaches" stated Dr. Jean Combalbert, CEO. “Euroscreen reinforces its leadership in innovative drugs targeting GPCR receptors through its ESN364 clinical development investment.”
Clinical Need and Market Opportunity
Endometriosis and Uterine Fibroids are serious public health concerns affecting approximately 10% of women around the world. GlobalData estimates that the combined global therapeutics market by 2018 for these two indications will be $2.8 billion. PCOS is another important disease with increasing incidence and a projected therapeutic market of $800 million by 2018. There are no broadly accepted therapies for this underserved market.
Euroscreen is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including hormonal disorders, inflammation and neurodegenerative diseases. The company has a drug discovery track-record with multiple innovative and proprietary small-molecules targeting GPCRs.
Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health disorders. Euroscreen is also actively seeking partners for its preclinical development candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis. Euroscreen is backed by leading investors, including Vesalius Biocapital, SRIW and Fortis Private Equity.
Further information about Euroscreen and its drug discovery and development programs can be found online at http://www.euroscreen.com or by contacting info(at)euroscreen(dot)com.